Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Down Today?

Why TLX stock is down today

Telix Pharmaceuticals ADR (TLX) fell 9.22% to $11.28 on August 21, 2026, following the release of its first-half 2026 earnings. The stock opened with a 7.4% gap down from the previous close of $12.42 and traded in a narrow range throughout the session. The decline reflects investor reaction to the company's financial results and broader market dynamics.

What Happened

Telix Pharmaceuticals reported first-half 2026 revenue of $477 million, representing a 22% year-over-year increase. The company highlighted margin improvements and strong commercial execution in its precision medicine imaging products. However, the stock reacted negatively to the earnings release, opening at $11.50 and falling to a session low of $11.19. The earnings call and related presentation, published on August 20 and 19, emphasized late-stage pipeline momentum and R&D investment but failed to offset the downward pressure. Additionally, Wedbush reiterated an Outperform rating with a $22 price target, but the market appears to have discounted this guidance in favor of more immediate concerns.

What The Data Shows

The stock has traded between $6.28 and $12.60 over the past 52 weeks. With a market cap of $4.1 billion, Telix remains unprofitable, reporting a net loss of $0.02 per share in the trailing twelve months. Revenue growth has been robust, with a 55.6% increase year-to-date. The session's volume of 0.0 million shares was below the 3-month average, suggesting limited participation. On August 21, the stock printed 13 fresh 52-week lows, indicating broader distribution pressure.

What To Watch

Telix has no upcoming earnings report scheduled in the near term. Investors should monitor the breadth of coverage and any shifts in analyst sentiment as the company progresses through key clinical and regulatory milestones in its pipeline.